10-Q: Inotiv Faces Going Concern Doubt Amidst Losses, Debt Maturities

Inotiv, Inc. reports increased net loss and negative cash flow, raising substantial doubt about its ability to continue as a going concern, despite growth in its DSA segment.

Summary

• Consolidated net loss increased to $28,378 thousand for the three months ended December 31, 2025, compared to $27,630 thousand in the prior year period.
• Total revenue saw a slight increase of 0.8% to $120,879 thousand, driven by a 12.0% increase in Discovery and Safety Assessment (DSA) revenue, partially offset by a 5.4% decrease in Research Models and Services (RMS) revenue.
• Cash and cash equivalents decreased significantly to $12,732 thousand as of December 31, 2025, from $21,741 thousand at September 30, 2025.
• Net cash used in operating activities increased to $5,433 thousand for the quarter, up from $4,497 thousand in the same period last year.
• All major debt facilities, including Term Loan Facility, Delayed Draw Term Loan, Incremental Term Loans, and the Revolving Credit Facility, are classified as current liabilities and mature in November 2026.
• The company's fiscal 2026 annual operating plan forecasts noncompliance with financial covenants for the remainder of fiscal 2026.
• An Eighth Amendment to the Credit Agreement waived certain financial covenants (First Lien Leverage Ratio and Fixed Charge Coverage Ratio) for the quarter ended December 31, 2025, but increased the minimum liquidity covenant to $30,000 thousand starting March 6, 2026.
• The Securities Class Action lawsuit was settled for an $8,750 thousand cash payment, fully funded by insurance, and derivative lawsuits are subject to a proposed settlement including corporate governance changes.
• Material weaknesses in internal control over financial reporting persist, particularly concerning IT general controls and the overall assessment process.
• Received a Nasdaq delisting notice for failing to maintain a minimum bid price of $1.00, with a compliance period until June 29, 2026.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this filing as highly negative due to the explicit 'substantial doubt about the Company's ability to continue as a going concern,' increased net losses, significant cash burn, and the classification of all major debt as current liabilities. The Nasdaq delisting notice and persistent material weaknesses in internal controls further compound the negative outlook, despite some positive segment performance.

Positives

• Discovery and Safety Assessment (DSA) segment revenue increased by 12.0% to $47,955 thousand, driven by increased discovery pharmacology and surgical services.
• DSA operating income significantly improved by 61.8% to $3,149 thousand.
• The book-to-bill ratio for the DSA services business was strong at 1.16x for the quarter.
• DSA backlog increased to $145,413 thousand at December 31, 2025, up from $130,392 thousand a year prior.
• Settlement of the Securities Class Action for $8,750 thousand was fully funded by available insurance, resolving significant litigation uncertainty.
• Proposed settlement of Derivative Actions includes corporate governance enhancements, such as a separate CEO and independent Board Chairperson, M&A due diligence guidelines, and a disclosure committee for at least five years.

Negatives

• Consolidated net loss increased to $28,378 thousand from $27,630 thousand in the prior year quarter.
• Operating loss increased to $16,330 thousand from $15,507 thousand.
• Research Models and Services (RMS) segment revenue decreased by 5.4% to $72,924 thousand, primarily due to lower non-human primate (NHP) volumes sold.
• RMS operating loss significantly worsened to $3,554 thousand from $1,185 thousand in the prior year quarter.
• Cash and cash equivalents declined by $9,009 thousand during the quarter, ending at $12,732 thousand.
• Net cash used in operating activities increased to $5,433 thousand, indicating higher cash burn from operations.
• All outstanding debt, totaling $405,773 thousand, is classified as current due to probable non-compliance with financial covenants and upcoming maturities in November 2026.
• Management's fiscal 2026 annual operating plan forecasts noncompliance with financial covenants for the remainder of fiscal 2026.
• The minimum liquidity covenant was increased to $30,000 thousand starting March 6, 2026, from $10,000 thousand, indicating heightened lender concern.
• Received a Nasdaq delisting notice for failing to maintain a minimum bid price of $1.00 per share.
• Material weaknesses in internal control over financial reporting persist, specifically in IT general controls and the process for assessing internal control effectiveness.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern due to negative operating cash flows, operating losses, consolidated net losses, and forecasted noncompliance with financial covenants.
• Failure to comply with financial covenants under the Credit Agreement could lead to an event of default, allowing lenders to accelerate all outstanding debt, which would also trigger defaults on Convertible Senior Notes and Second Lien Notes.
• The company's existing cash and cash equivalents, combined with cash from operations, are not believed to be sufficient to fund operations, satisfy obligations, and repay all outstanding debt if accelerated.
• Access to the revolving credit facility would be restricted if an event of default occurs.
• There is no assurance that lenders will agree to amendments or extensions to the Credit Agreement, or that the company can raise additional capital on acceptable terms.
• Liquidity needs and covenant compliance depend on the ability to source and sell non-human primates (NHPs), fill expanded DSA capacity, generate cash from other operating activities, and manage capital expenditures.
• Ongoing privacy class actions related to the 2025 Cybersecurity Incident seek unspecified monetary damages and injunctive relief, with potential material operational and financial impacts still being evaluated.
• The Nasdaq delisting notice for failing to meet the minimum bid price rule could adversely affect market liquidity, the ability to obtain financing, and investor confidence, potentially leading to a further decline in share price.
• External factors such as tariffs on imported NHPs (15% to 20%) negatively impact cash flows and may continue to do so, with no assurance of successful mitigation.
• Client research and development funding levels, particularly from government sources like the U.S. National Institutes of Health (NIH), are challenging to forecast and can impact both segments.
• The FDA Modernization Act 2.0, encouraging alternatives to animal testing, could impact demand for traditional animal research models.

Future Outlook

Management's fiscal 2026 annual operating plan forecasts noncompliance with its financial covenants under the Credit Agreement for the remainder of fiscal 2026. The company is exploring potential debt refinancing alternatives but offers no assurance that lenders will agree to amendments or extensions, or that additional capital can be raised. The company plans to continue efforts to optimize capital allocation and expense base, improve operating results with a focus on client service and margin discipline, and increase DTS and safety assessment contract awards and RMS product and service revenue. Phase Two of the RMS site optimization plan is expected to be complete by the end of the third fiscal quarter of 2026, aiming for $6,000 to $7,000 thousand in net annual savings. The company intends to monitor its common share bid price and consider options, including a reverse stock split, to regain Nasdaq compliance. The full operational and financial impacts of the 2025 Cybersecurity Incident are still being evaluated, and it has not yet been determined if they will be material.

Management Comments

• Management's fiscal 2026 annual operating plan forecasts noncompliance with its financial covenants pursuant to the Credit Agreement for the remainder of fiscal 2026.
• Management believes its existing cash and cash equivalents, together with cash generated from operations, will be sufficient to fund its operations and satisfy its obligations, including cash outflows for planned targeted capital expenditures for at least the next 12 months, excluding the maturity of the Company's Term Loan Facility, Delayed Draw Term Loan and Incremental Term Loans in November 2026.
• Management believes future objectives are in line with the goals outlined in the FDA Modernization Act 2.0, citing current service offerings like predictive computer software, computational toxicology, bioinformatics, proteomics, ex vivo and in vitro cell-based assays, and assays in human cells and tissues.
• Management intends to continue to monitor the bid price for common shares and will consider available options to resolve the deficiency and regain compliance with the Minimum Bid Price Rule, including seeking shareholder approval of a reverse split.

Industry Context

StockSavvy.ai notes that Inotiv operates in the contract research organization (CRO) sector, which is influenced by pharmaceutical and medical device R&D spending. The company's focus on nonclinical and analytical drug discovery and development services, alongside research models, positions it within a critical but evolving part of the drug development pipeline. The FDA Modernization Act 2.0, which encourages alternatives to animal testing, represents a significant industry trend. Inotiv's proactive mention of its alignment with this trend through offerings like computational toxicology and cell-based assays suggests an awareness of shifting regulatory and ethical landscapes. However, the reliance on non-human primates (NHPs) for a significant portion of its RMS revenue, coupled with tariff impacts and supply chain challenges, highlights a vulnerability in a segment facing increasing scrutiny and potential disruption. The cybersecurity incident also reflects a growing industry-wide risk for companies handling sensitive research data.

Comparison to Industry Standards

• NA

Corporate Governance

Legal Proceedings

• Securities Class Action lawsuit (Grobler v. Inotiv, Inc., et al.) settled for $8,750 thousand, fully funded by insurance, with final court approval on January 27, 2026.
• Shareholder Derivative Lawsuits (Grobler, Burkhart, Whitfield, Castro) reached an agreement in principle to settle, with a Proposed Derivative Settlement preliminarily approved on January 7, 2026, and a settlement hearing scheduled for March 18, 2026. The settlement includes corporate governance measures and attorneys' fees up to $2,250 thousand, expected to be insurance-funded.
• Three Privacy Class Actions (Doyal, Merrell, Wagner) consolidated under 'In re: Inotiv, Inc. Data Incident Litigation' following the 2025 Cybersecurity Incident, seeking unspecified monetary damages and injunctive relief. The company moved to dismiss the amended consolidated complaint on January 9, 2026.
• Envigo Class Action and PAGA Settlement for California wage and hour violations agreed to for $795 thousand, with preliminary court approval on June 12, 2025, and a final approval hearing scheduled for March 17, 2026.
• Resolution Agreement and Plea Agreement with the DOJ: Envigo pleaded guilty to a misdemeanor conspiracy to violate the Animal Welfare Act, and Envigo Global Services, Inc. (EGSI) pleaded guilty to a felony conspiracy to violate the Clean Water Act. This includes $22,000 thousand in fines, $3,000 thousand to taskforces, $3,500 thousand to a foundation, and $7,000 thousand for animal welfare improvements, along with a compliance monitor and probation for up to five years.

Related Party Transactions

• Seller Note Bolder BioPath: $94 thousand outstanding as of December 31, 2025.
• Seller Payable Orient BioResource Center: $3,235 thousand outstanding as of December 31, 2025, with maturity extended to March 27, 2026, and accruing interest at 4.60% per annum since July 27, 2024.

Stakeholder Impact

• Shareholders face significant risk due to the 'going concern' doubt, potential Nasdaq delisting, and the need for future capital raises, which could dilute existing equity or increase debt burden.
• Creditors (lenders and noteholders) are exposed to substantial risk given the company's forecasted noncompliance with debt covenants and the upcoming maturities of over $400,000 thousand in debt, which could lead to acceleration of obligations.
• Employees may experience uncertainty due to ongoing site optimization plans, which involve reducing production capacity, and the overall financial instability of the company.
• Customers in the biopharmaceutical and medical device industries may face concerns regarding the company's long-term stability and ability to consistently provide services and research models, particularly given the NHP supply challenges and legal issues.
• Regulatory authorities (SEC, Nasdaq, DOJ) are actively involved, with the SEC receiving this 10-Q, Nasdaq issuing a delisting notice, and the DOJ having secured plea agreements and imposed compliance monitoring, indicating high scrutiny of the company's operations and financial reporting.

Next Steps

• Continue efforts to optimize capital allocation and expense base.
• Improve operating results with a sustained focus on client service and margin discipline.
• Increase volume of Discovery and Translational Sciences (DTS) and safety assessment contract awards.
• Increase Research Models and Services (RMS) product and service revenue.
• Complete Phase Two of the RMS site optimization plan by the end of the third fiscal quarter of 2026.
• Monitor the bid price for common shares and consider options, including a reverse stock split, to regain Nasdaq compliance by June 29, 2026.
• Continue discussions with lenders regarding current business conditions and potential debt refinancing alternatives.
• Attend the settlement hearing for the Proposed Derivative Settlement on March 18, 2026.
• Await final approval hearing for the Envigo Class Action settlement on March 17, 2026.
• Continue remediation efforts for material weaknesses in internal control over financial reporting, including improving ITGCs and enhancing control environment.

Key Dates

Recommendation

The filing presents a highly concerning financial picture, with management explicitly stating 'substantial doubt about the Company's ability to continue as a going concern.' This is driven by persistent net losses, negative operating cash flows, and the classification of over $400 million in debt as current liabilities due to forecasted covenant non-compliance and imminent maturities. The Nasdaq delisting notice further exacerbates the risk, signaling a loss of market confidence and potential liquidity issues. While there are some positive developments in the DSA segment and legal settlements, these are overshadowed by the severe liquidity crunch, high debt burden, and ongoing material weaknesses in internal controls. The company's ability to refinance its debt or raise additional capital is uncertain. For a seasoned investor, these factors point to a high probability of significant capital impairment, making a 'strong sell' recommendation appropriate.

Keywords

Contract Research Organization, CRO, Drug Discovery, Drug Development, Preclinical, Research Models, Safety Assessment, Non-human Primates, Liquidity, Going Concern, Debt Covenants, Nasdaq Delisting, Cybersecurity Incident, Litigation Settlement, Financial Performance, Biopharmaceutical, Medical Device, Animal Welfare Act, Clean Water Act